Elsevier

Thrombosis Research

Volume 77, Issue 6, 15 March 1995, Pages 531-542
Thrombosis Research

Chloroquine inhibits stimulated platelets at the arachidonic acid pathway

https://doi.org/10.1016/0049-3848(95)00028-3Get rights and content

Abstract

Chloroquine inhibited arachidonic acid liberation from membrane phospholipids of thrombin and A23187- stimulated platelets. In addition, it dose-dependently inhibited stimulated malondialdehyde formation and thromboxane B2 generation in the same platelets. The linear correlation between the inhibition of arachidonic acid liberation and malondialdehyde formation indicated that chloroquine inhibited activated phospholipase A2 in thrombin-stimulated platelets, similarly as it does in different cells and tissues. Yet, the nonlinear relationship between arachidonic acid liberation along with malondialdehyde formation and thromboxane generation as well as aggregation suggest that phospholipase A2 does not seem to be the only site of chloroquine action. Rather, it may affect platelets either at other levels of the arachidonic acid cascade too, or at some different stimulatory pathways, like intraplatelet calcium mobilisation, phosphoinositide cycle, calmodulin and protein kinase C activation.

References (44)

  • MacintyreA.C. et al.

    In vitro binding of chloroquine to rat muscle preparation

    J Pharm Sci.

    (1986)
  • GinsburgH. et al.

    Current concepts and new perspective on the mechanism of action of quinoline containing antimalarials

    Biochem Pharmacol

    (1987)
  • PappuA. et al.

    Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver phospholipase A

    Biochem Pharmacol

    (1984)
  • GirkeS. et al.

    Comparison between the activities of cationic amphiphilic drugs to affect phospholipid membranes and to depress cardiac function

    Biochem Pharmacol

    (1989)
  • MccreaJ.M. et al.

    Mepacrine (quinacrine) inhibition of thrombin-induced platelet responses can be overcome by lysophosphatidic acid

    Biochim Biophys Acta

    (1985)
  • NozawaY. et al.

    Phospholipid-mediated signalling in receptor activation in human platelets

    Biochim Biophys Acta

    (1991)
  • Nosál'R. et al.

    The role of intracellular calcium in A23187 stimulated and beta-adrenoceptor blocking drug treated blood platelets

    Biochem Pharmacol

    (1994)
  • KaywakeS. et al.

    Effects of chloroquine and nifedipine on the phospholipid content and enzymatic activity in the subcellular fraction of ischemic rat liver

    Basic Res Cardiol

    (1982)
  • BerqvistY. et al.

    Distribution of chloroquine and its metabolite desetyl-chloroquine in human blood cells and its implication for the quantitative determination of these components in serum and plasma

    J Chromatogr

    (1983)
  • McchesneyE.W. et al.

    4-aminoquinolines

  • De DuweC. et al.

    Lysosomotropic agents

    Biochem Pharmacol

    (1974)
  • Nosál'R. et al.

    Distribution of chloroquine in human blood fractions

    Meth Find Exp Clin Pharmacol

    (1988)
  • Cited by (39)

    • Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?

      2021, Journal of Microbiology, Immunology and Infection
      Citation Excerpt :

      The antithrombotic properties of HCQ was described as far as 1975.5 In the context of autoimmune disease (SLE), HCQ inhibits stimulated platelets at the arachidonic acid pathway and thromboxane 2 generation in activated platelets (an activator of platelets aggregation), which is associated with decreased circulating levels of endothelin-1, and allows improvement of endothelial function.3,6–8 Interestingly, using network-based approach to prediction and population-based validation of in silico drug repurposing it was found that the Healthcare registry data for 220 million people showed that HCQ intake (a series of 37,795 patients receiving HCQ) was associated with a lower risk for coronary artery disease.9

    • COVID-19: Immunology and treatment options

      2020, Clinical Immunology
      Citation Excerpt :

      Furthermore, preventing the acidification of lysosomes, hydroxychloroquine impairs cellular autophagy, a critical step for innate and adaptive immunity activation [132]. Finally, hydroxychloroquine has antithrombotic effects, which may be beneficial in COVID-19, where inflammatory stimuli and endothelial injury activate coagulation and promote micro-thrombus formation [133,134]. While generally deemed safe when administered at correct dosing and under close monitoring, the therapeutic range of chloroquine and its derivatives is narrow.

    • Effects of 5,8-dimethylthieno[2,3-b]quinoline-2-carboxylic acid on the antioxidative defense and lipid membranes in Plasmodium berghei-infected erythrocytes

      2015, Experimental Parasitology
      Citation Excerpt :

      In this context, Jackson et al. (1984) demonstrated the ability of chloroquine to induce oxidative stress and to inhibit lipid peroxidation, possibly as a phospholipase-A2 inhibitor. Indeed, it was reported that this compound inhibited arachidonic acid liberation from membrane phospholipids (Nosál et al., 1995), thus, due to the same quinolone basic structure, TQCA could also inhibit lipid peroxidation by this mechanism. Further studies are needed to confirm this hypothesis.

    • Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome

      2015, Autoimmunity Reviews
      Citation Excerpt :

      In a dose-dependent fashion, HCQ and CQ can reduce collagen-induced platelet aggregation and platelet alpha-granule release [24,25]. HCQ can also reduce ADP-induced and/or ristocetin platelet aggregation [23,24], as well as arachidonic acid release by activated platelets [26]. This effect seems to be related to the inhibition of phospholipase A2 activation.

    View all citing articles on Scopus
    View full text